ABC294640 in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ABC294640 in treating patients
with advanced solid tumors. ABC294640 may stop the growth of tumor cells by blocking some of
the enzymes needed for cell growth. Please note that the FDA OOPD is participating as a
funding source.
Phase:
Phase 1
Details
Lead Sponsor:
RedHill Biopharma Limited
Collaborators:
Apogee Biotechnology Corporation FDA Office of Orphan Products Development Medical University of South Carolina National Cancer Institute (NCI)